Literature DB >> 2969305

Concentration and time dependence of the toxicity of fluorinated pyrimidines to HT 29 colorectal carcinoma cells.

K H Link1, K R Aigner, K Peschau, M Warthona, K Schwemmle, P V Danenberg.   

Abstract

To determine the optimal concentration time factors for the fluoropyrimidines 5-fluorouracil (FU), 5-fluorouridine (FUR), and 5-fluoro-2'-deoxyuridine (FUdR) in regional chemotherapy, we tested these drugs against the colorectal carcinoma cell line HT 29 at various dosages and exposure times. The measure of cytotoxicity used was the degree of inhibition of colony formation in soft agar after drug treatment compared with untreated control cells. Colonies were visible after 6 days of growth in soft agar, so the initial evaluation of toxicity was done at this time. Additional colonies were found 10 and 16 days after the first evaluation, so the dishes containing the treated cells were also evaluated for this delayed growth phenomenon ("regrowth"), which we considered to be due to a cell growth inhibition effect of the drugs rather than a cytocidal effect. Exposure times of the cells to the drugs ranged from 5 min to 24 h and the doses, between 0.01 and 1000 micrograms/ml. The toxicity of FUdR was concentration-dependent, but its time dependence ceased after a relatively short exposure time. There was a cell population that was not susceptible to FUdR regardless of dose and exposure time; consequently, FUdR treatment was always accompanied by substantial regrowth of colonies. With FU and FUR, conditions could be achieved that resulted in complete cell death (no regrowth), but high concentrations and long exposure times were required with FU. With FUR, on the other hand, both cytostasis and cytotoxicity could be achieved with substantially lower doses and shorter exposure times than with FU. These results indicate that FUR has the potential to be an effective drug in chemotherapy protocols not involving systemic administration.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2969305     DOI: 10.1007/bf00254182

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  13 in total

1.  Inhibition of ribosomal ribonucleic acid maturation in Novikoff hepatoma cells by 5-fluorouracil and 5-fluorouridine.

Authors:  D S Wilkinson; H C Pitot
Journal:  J Biol Chem       Date:  1973-01-10       Impact factor: 5.157

Review 2.  Fluorinated pyrimidines and their nucleosides.

Authors:  C Heidelberger; P V Danenberg; R G Moran
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1983

Review 3.  The pharmacology of the fluoropyrimidines.

Authors:  C E Myers
Journal:  Pharmacol Rev       Date:  1981-03       Impact factor: 25.468

Review 4.  Comparison of systemic chemotherapy with hepatic arterial infusion in metastatic colorectal carcinoma.

Authors:  M S Huberman
Journal:  Semin Oncol       Date:  1983-06       Impact factor: 4.929

5.  Time-dose relationships for 5-fluorouracil cytotoxicity against human epithelial cancer cells in vitro.

Authors:  P M Calabro-Jones; J E Byfield; J F Ward; T R Sharp
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

6.  Hepatic artery chemotherapy: the relative importance of direct organ distribution vs. the constant-infusion schedule.

Authors:  J J Lokich
Journal:  Am J Clin Oncol       Date:  1984-04       Impact factor: 2.339

7.  Prolonged and continuous percutaneous intra-arterial hepatic infusion chemotherapy in advanced metastatic liver adenocarcinoma from colorectal primary.

Authors:  R A Oberfield; J A McCaffrey; J Polio; M E Clouse; T Hamilton
Journal:  Cancer       Date:  1979-08       Impact factor: 6.860

8.  Colorectal cancer: chemotherapy as surgical adjuvant treatment.

Authors:  C G Moertel
Journal:  Bull Cancer       Date:  1983       Impact factor: 1.276

Review 9.  Treatment of cultured human colon carcinoma cells with fluorinated pyrimidines.

Authors:  B Drewinko; L Y Yang; D H Ho; J Benvenuto; T L Loo; E J Freireich
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

10.  Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion.

Authors:  R J Fraile; L H Baker; T R Buroker; J Horwitz; V K Vaitkevicius
Journal:  Cancer Res       Date:  1980-07       Impact factor: 12.701

View more
  8 in total

1.  Toxicity and effects of adjuvant therapy in colon cancer: results of the German prospective, controlled randomized multicenter trial FOGT-1.

Authors:  L Staib; K H Link; H G Beger
Journal:  J Gastrointest Surg       Date:  2001 May-Jun       Impact factor: 3.452

2.  Pharmacokinetic properties and antitumor efficacy of the 5-fluorouracil loaded PEG-hydrogel.

Authors:  Hee Yi; Hee-Jung Cho; Soo-Min Cho; Dong-Goo Lee; A M Abd El-Aty; So-Jeong Yoon; Gun-Won Bae; Kwang Nho; Bokyung Kim; Chi-Ho Lee; Jin-Suk Kim; Michael G Bartlett; Ho-Chul Shin
Journal:  BMC Cancer       Date:  2010-05-18       Impact factor: 4.430

3.  Effects of oxaliplatin and CPT-11 on cytotoxicity and nucleic acid incorporation of the fluoropyrimidines.

Authors:  Manish Patel; Ram Agarwal; Bach Ardalan
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-15       Impact factor: 4.553

4.  Increased cytotoxicity of low-dose, long-duration exposure to 5-fluorouracil of V-79 cells with hyperthermia.

Authors:  Y Kido; H Kuwano; Y Maehara; M Mori; H Matsuoka; K Sugimachi
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 5.  Fabrication and Use of Poly(d,l-lactide-co-glycolide)-Based Formulations Designed for Modified Release of 5-Fluorouracil.

Authors:  Nattawut Leelakanok; Sean Geary; Aliasger Salem
Journal:  J Pharm Sci       Date:  2017-10-16       Impact factor: 3.784

6.  Pharmacokinetic modulation of plasma 5-fluorouracil concentrations to potentiate the antitumor activity of continuous venous infusion of 5-fluorouracil.

Authors:  S Fujii; M Fukushima; Y Shimamoto; T Shirasaka
Journal:  Jpn J Cancer Res       Date:  1989-06

Review 7.  Patient-centered developments in colon- and rectal cancer with a multidisciplinary international team: From translational research to national guidelines.

Authors:  Karl-Heinrich Link; Marko Kornmann; Ludger Staib; Ernst-Dietrich Kreuser; Wilhelm Gaus; Erwin Röttinger; Peter Suhr; Catharina Maulbecker-Armstrong; Peter Danenberg; Kathleen Danenberg; Miriam Schatz; Silvia Sander; Zhen-Ling Ji; Jiang-Tao Li; Shu-You Peng; Reinhard Bittner; Hans Günther Beger; Benno Traub
Journal:  World J Gastrointest Surg       Date:  2021-12-27

8.  Effect of 5-fluorouracil combination therapy on RNA processing in human colonic carcinoma cells.

Authors:  D A Greenhalgh; J H Parish
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.